The aberrant signaling activation of vascular endothelial growth factor receptor (VEGFR) and urokinase plasminogen activator (uPA) is a common characteristic of many tumors, including lung cancer. Accordingly, VEGFR and uPA have emerged as attractive targets for tumor. KDR (Flk-1/VEGFR-2), a member of the VEGFR family, has been recognized as an important target for antiangiogenesis in tumor. In this study, a recombinant immunotoxin was produced to specifically target KDR-expressing tumor vascular endothelial cells and uPA-expressing tumor cells and mediate antitumor angiogenesis and antitumor effect. Based on its potent inhibitory effect on protein synthesis, Luffin-beta (Lβ) ribosome-inactivating protein was selected as part of a recombinant fusion protein, a single-chain variable fragment against KDR (KDRscFv)-uPA cleavage site (uPAcs)-Lβ-KDEL (named as KPLK). The KDRscFv-uPAcs-Lβ-KDEL (KPLK) contained a single-chain variable fragment (scFv) against KDR, uPAcs, Lβ, and the retention signal for endoplasmic reticulum proteins KDEL (Lys-Asp-Glu-Leu). The KPLK-expressing vector was expressed in Escherichia coli, and the KPLK protein was isolated with nickel affinity chromatography and gel filtration chromatography. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis test demonstrated KPLK was effectively expressed. Result of in vitro cell viability assay on non-small cell lung cancer (NSCLC) H460 cell line (uPA-positive cell) revealed that KPLK significantly inhibited cell proliferation, induced apoptosis, and accumulated cells in S and G2/M phases, but the normal cell line (human submandibular gland cell) was unaffected. These effects were enhanced when uPA was added to digest KPLK to release Lβ. For in vivo assay of KPLK, subcutaneous xenograft tumor model of nude mice were established with H460 cells. Growth of solid tumors was significantly inhibited in animals treated with KPLK up to 21 days, tumor weights were decreased, and the expression of angiogenesis marker CD31 was downregulated; meanwhile, the apoptosis-related protein casspase-3 was upregulated. These results suggested that the recombinant KPLK may have therapeutic applications on tumors, especially uPA-overexpressing ones.
Piastowska-CiesielskaAWPłuciennikEWójcik-KrowirandaKBieńkiewiczANowakowskaMPospiechKBednarekAKDomińskaKOchędalskiT. Correlation between VEGFR-2 receptor kinase domain-containing receptor (KDR) mRNA and angiotensin II receptor type 1 (AT1-R) mRNA in endometrial cancer. Cytokine2013; 61: 639–44.
JiangYChenKTangZZengZYaoWSunDKaWHeDWenZChienS. TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells. Cell Motil Cytoskeleton2006; 63: 471–82.
6.
Van CruijsenHGiacconeGHoekmanK. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer2005; 117: 883–8.
7.
DevIKDornsifeREHopperTMOnoriJAMillerCGHarringtonLEDoldKMMullinRJJohnsonJHCrosbyRMTruesdaleATEpperlyAHHinkleKWCheungMStaffordJALuttrellDKKumarR. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. Br J Cancer2004; 91: 1391–8.
8.
ZhuZHattoriKZhangHJimenezXLudwigDLDiasSKussiePKooHKimHJLuDLiuMTejadaRFriedrichMBohlenPWitteLRafiiS. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2: correlation between antibody affinity and biological activity. Leukemia2003; 17: 604–11.
9.
KarashimaTInoueKFukataSIiyamaTKurabayashiAKawadaCShuinT. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Oncol2007; 30: 937–45.
10.
KouBLiYShiYXiaJWangXWuS. Gene therapeutic exploration: retrovirus mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo. Oncol Res2005; 15: 239–47.
11.
LiuSBuggeTHLepplaSH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem2001; 276: 17976–84.
12.
ZhangXFeiZBuXZhenHZhangZGuJChenY. Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J Surg Oncol2000; 74: 90–4.
13.
HasegawaYKinohHIwadateYOnimaruMUedaYHaradaYSaitoSFuruyaASaegusaTMorodomiYHasegawaMSaitoSAokiISaekiNYonemitsuY. Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-beta gene. Mol Ther2010; 18: 1778–86.
14.
de VirgilioMLombardiACaliandroRFabbriniMS. Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins (Basel)2010; 2: 2699–737.
15.
NgYMYangYSzeKHZhangXZhengYTShawPC. Structural characterization and anti-HIV-1 activities of arginine/glutamate-rich polypeptide Luffin P1 from the seeds of sponge gourd (Luffa cylindrica). J Struct Biol2011; 74: 164–72.
16.
NilssonLAsanoKSvenssonBPoulsenFMNygårdO. Reduced turnover of the elongation factor EF-1 X ribosome complex after treatment with the protein synthesis inhibitor II from barley seeds. Biochim Biophys Acta1986; 868: 62–70.
17.
CassellAGrandisJR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs2010; 19: 709–22.
18.
LiuLWangRHeWHeFHuangG. Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro. Acta Biochim Biophys Sin Shanghai2010; 42: 585–92.
19.
YanLXiangweiMXiaoLPengGChangLMingyaoTEnchengYXiaohongXPengJShifuKZhongmeiWNingyiJ. Construction, expression and characterization of a dual cancer-specific fusion protein targeting carcinoembryonic antigen in intestinal carcinomas. Protein Expr Purif2010; 69: 120–5.
20.
NgTBWongRNYeungHW. Two proteins with ribosome-inactivating, cytotoxic and abortifacient activities from seeds of Luffa cylindrica roem Cucurbitaceae. Biochem Int1992; 27: 197–207.
21.
LingJLiuWYWangTP. Cleavage of supercoiled double-stranded DNA by several ribosome-inactivating proteins in vitro. FEBS Lett1994; 345: 143–6.
22.
PomaAMirandaMSpanoL. Differential response of human mela-noma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin. Melanoma Res1998; 8: 465–7.
23.
AuTKCollinsRALamTLNgTBFongWPWanDC. The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett2000; 471: 169–72.
24.
WangFEric KnabeWLiLJoIManiTRoehmHOhKLiJKhannaMMerouehSO. Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem2012; 20: 4760–73.
25.
MoritaSSatoAHayakawaHIharaHUranoTTakadaYTakadaA. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization. Int J Cancer1998; 78: 286–92.
26.
Qiying LiYing XiangWeiqian Yu. Study on the construction, expression and purification of the fused prokaryotic protein Luffin-β-KDEL-uPAcs and its cytotoxic effect on gastric carcinoma SGC-7901 cell line. J Third Mil Med Univ2013; 35: 774–8.
27.
Ying XiangQiying LiJianghong Wang. The vector construction and expression of Luffin-β targeted fusion immunotoxin as well as its inhibitory effect on non-small cell lung cancer cells. Tumor2013; 33: 314–20.
28.
NallTAChappellKJStoermerMJFangNXTyndallJDYoungPRFairlieDP. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem2004; 279: 48535–42.
29.
LinYYangXLuMZhuangHHuaZC. Expression, purification and biological characterization of human vasostatin120-180 in Pichia pastoris. Protein Expr Purif2013; 92: 141–7.
30.
CroucherDR1SaundersDNStillfriedGERansonM. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J2007; 408: 203–10.
31.
YanGSunHWangFWangJWangFZouZChengTAiGSuY. Topical application of hPDGF-A-modified porcine BMSC and keratinocytes loaded on acellular HAM promotes the healing of combined radiation-wound skin injury in minipigs. Int J Radiat Biol2011; 87: 591–600.
32.
KreitmanRJ. Immunotoxins in cancer therapy. Curr Opin Immunol1999; 11: 570–8.
33.
BarbieriLBolognesiAValbonesiPPolitoLOlivieriFStirpeF. Polynucleotide: adenosine glycosidase activity of immunotoxins containing ribosome-inactivating proteins. J Drug Target 2000; 8: 281–8.
34.
HerreraLYarbroughSGhetieVAquinoDBVitettaES. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia2003; 17: 334–8.
35.
SmallshawJEGhetieVRizoJFulmerJRTrahanLLGhetieMAVitettaES. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol2003; 21: 387–91.
36.
Jach G, Gornhardt B, Mundy J, Logemann J, Pinsdorf E, Leah R, Schell J, Maas C. Enhanced quantitative resistance against fungal disease by combinatorial expression of different barley antifungal proteins in transgenic tobacco. Plant J 1995;8:97–109.
37.
DowdPFZuoWNGillikinJWJohnsonETBostonRS. Enhanced resistance to Helicoverpa zea in tobacco expressing an activated form of maize ribosome-inactivating protein. J Agric Food Chem2003; 51: 3568–74.
38.
AstedtBHolmbergL. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature1976; 261: 595–7.
39.
NovotnyA1EdsparrKNylundGKhorram-ManeshAAlbertssonPNordgrenSDelbroDS. A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29. Eur J Pharmacol2010; 646: 22–30.
40.
ZhangY1KennyHASwindellEPMitraAKHankinsPLAhnRWGwinKMazarAPO'HalloranTVLengyelE. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Mol Cancer Ther2013; 12: 2628–39.
41.
ZongHWangFFanQXWangLX. Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways. Mol Biol Rep2012; 39: 4803–8.
42.
EckeTHSchlechteHHSchulzeGLenkSVLoeningSA. Four tumour markers for urinary bladder cancer–tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res2005; 25: 635–41.
43.
Horvatić HercegGHercegDKralikMBence-ZigmanZTomić-BrzacHKulićA. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr2006; 118: 601–9.
44.
LeeSBHoJNYoonSHKangGYHwangSGUmHD. Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. Mol Cells2009; 28: 583–8.
45.
BüchlerPReberHATomlinsonJSHankinsonOKallifatidisGFriessHHerrIHinesOJ. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia2009; 11: 196–206.
46.
ShettySIdellS. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch Biochem Biophys1998; 356: 265–79.
47.
AsuthkarSStepanovaVLebedevaTHoltermanALEstesNCinesDBRaoJSGondiCS. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell2013; 24: 2620–32.
48.
PlesnerTRalfkiaerEWittrupMJohnsenHPykeCPedersenTLHansenNEDanøK. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol1994; 102: 835–41.
49.
BiSLanzaFGoldmanJM. The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res1994; 54: 582–6.
50.
DanøKRømerJNielsenBSBjørnSPykeCRygaardJLundLR. Cancer invasion and tissue remodeling–cooperation of protease systems and cell types. APMIS1999; 107: 120–7.
51.
AndreasenPAEgelundRPetersenHH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci2000; 57: 25–40.
52.
Yeh JE, Toniolo PA, Frank DA. Targeting transcription factors: promising new strategies for cancer therapy. Curr Opin Oncol 2013;25:652–8.
53.
SchmittMHarbeckNThomssenCWilhelmOMagdolenVReuningUUlmKHöflerHJänickeFGraeffH. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost1997; 78: 285–96.
54.
FabbriniMSCarpaniDBello-RiveroISoriaMR. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J1997; 11: 1169–76.
55.
IppolitiRLendaroEBenedettiPATorrisiMRBelleudiFCarpaniDSoriaMRFabbriniMS. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J2000; 14: 1335–44.
56.
RajagopalVKreitmanRJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. J Biol Chem2000; 275: 7566–73.
